Fri, Apr 18, 2014, 1:14 AM EDT - U.S. Markets closed for Good Friday

Recent

% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

  • wilderguide wilderguide Jun 13, 2013 4:58 PM Flag

    Mass Gen hormone resistant mBC trial change

    $$$$
    Just wanted to point out an interesting protocol change that was posted with the 6/10/13 revision. I don't believe that combination treatment with fulvestrant was a part of the original trial design.

    "The single agent portion of this study is now closed to accrual. This research study is now examining the efficacy of cabozantinib in combination with fulvestrant for treatment of hormone-receptor-positive breast cancer that has spread to bone."

    GLTA

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Fwiw, this study (NCT01441947) was updated yesterday at clinicaltrialgov from 'recruiting' to 'ongoing, but not recruiting.'

      Sentiment: Strong Buy

    • $$$$
      There are a lot of publications that tend to explain the rationale for the combination of faslodex and cabo in mBC, but I couldn't find one more to the point than this study:

      "Chronic exposure to fulvestrant promotes overexpression of the c-Met receptor in breast cancer cells: implications for tumour-stroma interactions." PubMed 2006

      GLTA

 
EXEL
3.29-0.03(-0.90%)Apr 17 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.